Chronic myeloid leukaemia (CML) is characterised by an indolent, chronic phase (CP) preceding an acute transformation to blast crisis (BC). While the BCR-ABL fusion oncogene is strongly implicated in the CP, the molecular changes underlying BC are largely unknown. The ataxia telangiectasia gene, ATM, is a candidate gene for this transformation because the complex karyotypes associated with BC of CML suggest that DNA double-strand break repair is defective and because the ABL pathway involves the interaction between the Abl and the Atm proteins. We performed a mutational analysis for ATM in CML using genomic DNA from 14 CML cell lines and 59 CML patients in BC. No clearly deleterious nucleotide changes were observed. A new polymorphism C4138T was discovered which results in a non-conservative amino acid substitution (H1380Y 
Introduction
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder that classically evolves in three clinical stages: a chronic phase (CP) with a relatively benign phenotype, an accelerated phase (AP) characterised by increasing refractoriness to therapy, and a final acute transformation or blast crisis (BC) which is usually unresponsive to treatment and invariably fatal. The onset of CML is caused by the generation of the BCR-ABL oncogene in a t(9;22)(q34;q11) chromosomal translocation. The leukaemogenic nature of the encoded Bcr-Abl fusion protein relies on the fact that it has a constitutively activated tyrosine kinase which ultimately leads to a deregulated proliferation, decreased cell adherence and reduced apoptotic response to mutagenic stimuli. 1 The latter feature is believed to underlie the invariable evolution of the disease to BC, by facilitating the emergence of additional deleterious mutations. However, the known abnormalities in RAS, p53, RB and p16, 2-5 account for less than 30% of the BC. 3 The search for other possible causative mutations is naturally focused on genes that are relevant to the control of cell cycle, differentiation or apoptosis, and which have been associated with the genesis of other malignancies. 6, 7 Ataxia telangiectasia, a recessive disorder due to mutations in the ATM gene, is characterised by genomic instability and by early onset of solid and haematological malignancies. 8, 9 After X-irradiation, the Atm protein directly interacts with the Abl protein via 10 amino acids encoded by sequence within exon 30 10 and then phosphorylates Abl at Ser 465. 11 At the same time, the Atm protein interacts with and phosphorylates p53 Ser15 via residues encoded within ATM exons 61 to 65. 12, 13 This Atm protein kinase activity also has Chk2 as a substrate.
14 The last 10 exons encode a region called the PIKlike domain that shows extensive homology to phosphatidylinositol 3-and 4-kinases. 15 Sporadic forms of some of the haematological malignancies that are prevalent in A-T patients are mutated at ATM. In T cell prolymphocytic leukemia (T-PLL) half of cases acquire mutations and there is a clustering of missense mutations in exons 50 to 65. 16 ATM is also mutated in a B cell non-Hodgkin's lymphoma subtype and B cell chronic lymphocytic leukemia. [17] [18] [19] The number of mutations reported so far is small but consistent with clustering in exons 50 to 65.
ATM is a candidate gene in CML because the complex karyotypes associated with BC of CML suggest that there is genomic instability and because the ABL pathway is strongly implicated in CML and this pathway involves the interaction between the Abl and the Atm proteins. We therefore performed a mutation analysis of two regions of the ATM gene in CML cases and cell lines: the region involved in the interaction with Abl and the mutational cluster region comprising the last 15 exons of ATM.
Materials and methods

Study population
Fourteen cell lines established from the blast crisis (BC) of CML were investigated: K562, KCL22, KYO1, KU812, LAMA84, BV173, EM3, EM2, NALM1, CML-T1, AR230, SD1, TOM1 and MEG-01. These lines 20 were either purchased from cell repository banks (American Type Culture Collection, Rockville, MD, USA; European Collection of Cell Cultures, Winchester, UK; or German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) or kindly donated by their originators. Cells were grown in RPMI1640 (Gibco-BRL, Paisley, UK) supplemented with penicillin, streptomycin, L-glutamine and 10% fetal calf serum.
Peripheral blood leucocytes from 59 patients with CML in BC and 83 healthy adult volunteers were obtained by red cell lysis. For some of the latter group, buccal epithelial cells from saline mouthwash were used instead of or in addition to blood leucocytes. The BC leucocyte suspensions were further fractionated by density centrifugation and the mononuclear cells containing 85-95% of blasts were isolated for the mutation analysis. All samples were obtained after informed consent.
Mutation detection
DNA was extracted by conventional methods and 50 ng was used in polymerase chain reaction (PCR) amplification using primers designed for exons 27 to 33 and exons 50 to 65. Exons are numbered according to Uziel et al. 21 Primer sequences were in the flanking introns (except for reverse primer for exon 32 dCTP in a 96-well plate, using the Hybaid Touchdown sub-ambient apparatus (Hybaid, Ashford, UK). Where a PCR product was longer than 250 bp, it was digested with an appropriate restriction enzyme to yield two or three fragments prior to single-strand conformation polymorphism (SSCP). PCR product in 50% formamide was heat-denatured, snapchilled and fractionated for 6 h at room temperature at 15 W on a 6% polyacrylamide gel containing 10% glycerol. The gel was dried down on a sheet of 3MM paper and visualised by autoradiography. Some samples gave rise to abnormal bands. These samples were re-amplified with the original primers, subcloned in the TOPO-TA vector (Invitrogen, Groningen, The Netherlands) following the manufacturer's protocol, and sequenced with M13 primers and the Big Dye kit (Applied Biosystems Warrington, UK) on an ABI Prism 377 DNA Sequencer (Applied Biosystems). Nucleotides (nt) are identified by counting from the first base of the first codon of ATM cDNA (GenBank accession number U33841, nucleotide 190).
Results
DNA was prepared from 14 CML cell lines and 59 patients in BC of CML, amplified with primers for ATM exons 27-33 and exons 50-65 and subjected to SSCP gel fractionation. Additional bands abnormal in position were detected in exon 30 for NALM1 and in exon 31 in two patients (Figure 1 ). In
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Figure 1
Autoradiogram of SSCP mutation detection for ATM exon 31. Labelled PCR products were digested with EcoRI and fractionated by SSCP. The arrow indicates an extra band seen in one CML patient in blast crisis and in chronic phase (BC1 and CP1, respectively) and in a second CML patient in blast crisis. one of these two patients a DNA sample from diagnosis at CP was shown to have the same additional band.
Sequencing of the abnormal PCR products identified C4138T (H1380Y) in NALM1, and C4258T (L1420F) in the two patients. C4138T results in the loss of an MnlI site and so can be detected by its resistance to restriction (Figure 2) . Screening of 78 healthy persons identified one heterozygote with C4138T. SSCP analysis of 83 healthy persons for exon 31 identified one individual heterozygous for C4258T (Table 1) .
Discussion
This study was undertaken to assess the contribution of ATM to the blastic transformation of CML by mutation detection analysis of two key regions of ATM. DNA from 73 samples was examined for mutations in ATM exons encompassing the No clearly deleterious nucleotide changes were detected in the CML samples. However, a non-conservative amino acid change H1380Y (C4138T) was discovered that lies directly within the Abl-binding motif DPAPNPPHFP in exon 30 and two samples had a nearby rare polymorphism, C4258T, causing a non-conservative amino acid change (L1420F) that has been reported previously. 22, 23 Both nucleotide changes detected in the CML samples appeared to have arisen on one allele.
It is likely that C4138T is a germline variant since the same variant was detected in a panel of healthy persons. However, there is evidence that some ATM germline variants recur as somatic mutations. 24 It will be of interest to determine if either H1380Y or L1420F affect the interaction of the Abl with the Atm protein. It will also be of interest to test the frequency of these probable polymorphisms in a fully matched population.
In conclusion, this study has provided evidence that tends to exclude mutations at ATM from playing any role in CML or its progression. These results were obtained by SSCP mutation detection, a technique that was validated by the identification of known and novel rare polymorphisms in both the CML and the normal populations studied. Moreover, the same assay has been used previously to identify frequent sequence changes in T-PLL 25, 26 and some B cell malignancies. 27 The molecular basis for the complex karyotypes detected in BC of CML remains unexplained. Future candidates for investigation should include genes which when mutated are associated with genomic instability and elevated risk of myeloid malignancy.
